Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 8Neoplasms 5Lymphoma, Mantle-Cell 4Breast Neoplasms 4Kidney Neoplasms 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma 2Urogenital Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × temsirolimus × Clear all
NCT00106353 2013-02-08

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Pfizer

Phase 1/2 Completed
71 enrolled 42 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡